

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM799407

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
MIDCAP FINANCIAL TRUST		03/30/2023	Statutory Trust: DELAWARE
RECEIVING PARTY DATA			
Name:	PARTNER THERAPEUTICS, INC.		
Street Address:	19 Muzzey St., Suite 105		
City:	Lexington		
State/Country:	MASSACHUSETTS		
Postal Code:	02421		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	1653426	LEUKINE	
Serial Number:	87900605	PARTNER THERAPEUTICS	
Registration Number:	5939060	PARTNER THERAPEUTICS	
Serial Number:	87900635	X	
Registration Number:	5909335	X	
CORRESPONDENCE DATA			
Fax Number:	9495676710		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	9498527792		
Email:	ipprosecution@orrick.com, vsantos@orrick.com		
Correspondent Name:	ORRICK, HERRINGTON & SUTCLIFFE LLP		
Address Line 1:	2050 Main Street, Suite 1100		
Address Line 4:	Irvine, CALIFORNIA 92614-8255		
ATTORNEY DOCKET NUMBER:	45678-14		
NAME OF SUBMITTER:	Victor Santos		
SIGNATURE:	/Victor Santos/		
DATE SIGNED:	03/31/2023		
Total Attachments: 6			

CH \$140.00 1653426

source=PTx - Release of Intellectual Property Security Interest (Term Loan)#page1.tif
source=PTx - Release of Intellectual Property Security Interest (Term Loan)#page2.tif
source=PTx - Release of Intellectual Property Security Interest (Term Loan)#page3.tif
source=PTx - Release of Intellectual Property Security Interest (Term Loan)#page4.tif
source=PTx - Release of Intellectual Property Security Interest (Term Loan)#page5.tif
source=PTx - Release of Intellectual Property Security Interest (Term Loan)#page6.tif

RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

This Release of Intellectual Property Security Interest , dated as of March 30, 2023, is made by **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust, (“**Agent**”), in favor of **PARTNER THERAPEUTICS, INC.**, a Delaware corporation (the “**Grantor**”):

WHEREAS, pursuant to that certain Intellectual Property Security Agreement, dated as of January 31, 2018 (as may have been further amended, modified, restated, replaced, reaffirmed or supplemented from time to time, the “**IP Security Agreement**”; capitalized terms used herein have the definition provided for in the IP Security Agreement), as reaffirmed pursuant to that certain Reaffirmation Agreement and Amendment to Intellectual Property Security Agreement dated as of April 30, 2021 recorded with the United States Patent and Trademark Office on May 4, 2021 at Reel/Frame No. 7279/0527 (Trademarks), and further reaffirmed pursuant to that certain Reaffirmation Agreement and Amendment to Intellectual Property Security Agreement dated as of December 30, 2022 recorded with the United States Patent and Trademark Office on January 6, 2023 at Reel/Frame No. 7940/0436 (Trademarks) and on January 6, 2023 at Reel/Frame No. 062306/0919 (Patents) wherein Grantor granted to Agent, on behalf of the Lenders, a security interest in and to all of its right, title and interest in all of Grantor’s intellectual property, including those listed on Exhibit A through D thereto;

WHEREAS, the Grantor has requested that Agent release its security interest in and to the patent assets as more particularly described on Schedule A attached hereto (the “**Released Patents**”).

WHEREAS, the Grantor has requested that Agent release its security interest in and to the trademark assets as more particularly described on Schedule B attached hereto (the “**Released Trademarks**”).

WHEREAS, the Grantor has requested that Agent release its security interest in and to the various intellectual property assets set forth in Sections (a) through (j) of the IP Security Agreement (together with the Released Patents and Released Trademarks, the “**Released IP Collateral**”).

NOW, THEREFORE, Agent, without recourse, representation or warranty and at Grantor’s sole cost and expense, hereby releases all of its right, title and interest in and to the Released IP Collateral.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Agent has caused this Release of Intellectual Property Security Interest to be duly executed and delivered by its duly authorized officer as of the date first written above.


AGENT:

MIDCAP FINANCIAL TRUST

as Agent

By: Apollo Capital Management, L.P.,
its investment manager

By: Apollo Capital Management GP, LLC,
its general partner

By: 
Name: Maurice Amsellem
Title: Authorized Signatory

Schedule A

Patents



Docket No.	Country Type	Title	Application Number and Date	Status / Comments
PNR-001PR	US Provisional	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED INFECTION TREATMENTS	US 63/014,462 Filed April 23, 2020	Converted
PNR-001PR2	US Provisional	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED INFECTION TREATMENTS	US 63/093,576 Filed October 19, 2020	Converted
PNR-001PC	International PCT	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED INFECTION TREATMENTS	PCT/US21/28875 Filed April 23, 2021	Converted
PNR-001	US Non-Provisional	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED INFECTION TREATMENTS	17/920,075 Filed October 20, 2022	PENDING
PNR-001JP	Japanese Non-Provisional	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED INFECTION TREATMENTS	2022-564376 Filed April 23, 2021	PENDING
PNR-003PR	US Provisional	GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS	US 63/105,425 Filed October 26, 2020	Converted
PNR-003PR2	US Provisional	GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS	US 63/177,481 Filed April 21, 2021	Converted
PNR-003PC	International PCT	GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS	PCT/US21/56413 Filed October 25, 2021	PENDING
PNR-004PR	US Provisional	MANUFACTURE OF GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR	US 63/122,593 Filed December 8, 2020	Converted
PNR-004PR2	US Provisional	MANUFACTURE OF GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR	US 63/271,444 Filed October 25, 2021	Converted

PNR-004PC	International PCT	MANUFACTURE OF GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR	PCT/US21/62168 Filed December 7, 2021	PENDING
PNR-006PR	US Provisional	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED CANCER TREATMENTS	US 63/280,737 Filed November 18, 2021	Converted
PNR-006PC	International PCT	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED CANCER TREATMENTS	PCT/US2022/080105 Filed November 18, 2022	PENDING
PNR-007PR	US Provisional	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED DERMATOLOGICAL PATHOLOGY TREATMENTS	US 63/301,707 Filed January 21, 2022	PENDING
PNR-007PR2	US Provisional	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED DERMATOLOGICAL PATHOLOGY TREATMENTS	US 63/347,766 Filed June 1, 2022	PENDING
PNR-007PR3	US Provisional	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED DERMATOLOGICAL PATHOLOGY TREATMENTS	US 63/413,772 Filed October 6, 2022	PENDING
PNR-008PR	US Provisional	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED TREATMENTS FOR NEURODEGENERATIVE OR NEUROLOGICAL DISEASES OR DISORDERS	US 63/308,220 Filed February 11, 2022	PENDING
PNR-009PR	US Provisional	LONG-ACTING GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR	US 63/329,039 Filed April 6, 2022	PENDING <i>(Subject to Biothus Agreement)</i>
PNR-010PR	US Provisional	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED TREATMENTS FOR PULMONARY OR RESPIRATORY DISEASES OR DISORDERS	US 63/347,781 Filed June 1, 2022	PENDING
PNR-011PR	US Provisional	BIOMARKERS FOR PARKINSON'S DISEASE	US 63/240,233 Filed September 2, 2021	Converted <i>(Exclusively licensed from University of Nebraska)</i>

PNR-011PR2	US Provisional	BIOMARKERS FOR PARKINSON'S DISEASE	US 63/303,102 Filed January 26, 2022	Converted <i>(Exclusively licensed from University of Nebraska)</i>
PNR-011PC	International PCT	BIOMARKERS FOR PARKINSON'S DISEASE	PCT/US22/75837 Filed September 1, 2022	PENDING <i>(Exclusively licensed from University of Nebraska)</i>

Schedule B

Trademarks

Name / Identifier of IP	Registration/ Publication or Application Number	Filing Date/Expiration Date
LEUKINE	TMA430098	November 2, 1989
LEUKINE	1653426	October 13, 1989
PARTNER THERAPEUTICS	87900605	April 30, 2018
PARTNER THERAPEUTICS	5939060	December 17, 2019
	87900635	April 30, 2018
	5009335	November 12, 2019